Docoh
Loading...

GSK Glaxosmithkline

Filed: 18 Feb 21, 6:46am
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
 
 
For the month of February 2021
 
Commission File Number 001-15170
 
 
GlaxoSmithKline plc
(Translation of registrant's name into English)
 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive office)
 
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
 
 
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
 
 
GlaxoSmithKline plc (the 'Company')
 
Transaction notification
 
1.Details of PDMR/person closely associated with them ('PCA')
a)NameMr R Simard
b)Position/statusPresident, Pharmaceuticals Supply Chain
c)Initial notification/amendmentInitial notification
2.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameGlaxoSmithKline plc
b)LEI5493000HZTVUYLO1D793
3.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
b)Nature of the transactionFollowing the vesting on 15 February 2021 of an award made on 6 September 2018 under the GlaxoSmithKline Deferred Investment Award programme in lieu of a Share Value Plan award, Mr Simard will receive a cash payment of £142,364.32 less applicable tax withholding in respect of 11,060 notional Ordinary Shares.
c)Price(s) and volume(s) Price(s)Volume(s) 
 £12.87211,060 
    
d)Aggregated information 
N/A (single transaction)
Aggregated volume Price 
e)Date of the transaction2021-02-16
f)Place of the transaction
N/A
 
 
 
 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
 GlaxoSmithKline plc
 (Registrant)
  
Date: February 18, 2021 
  
 
By:/s/ VICTORIA WHYTE
--------------------------
  
 Victoria Whyte
 Authorised Signatory for and on
 behalf of GlaxoSmithKline plc